News
RXRX
8.07
+4.81%
0.37
Moderna and OpenAI in pact to fast-track drug development
Healthcare Tech Moderna and OpenAI in pact to fast-track drug development. About 3,000 employees at Massachusetts-based biotech Moderna will have access to AI firm's ChatGPT Enterprise. Moderna has partnered with AI firm OpenAI to deploy the technology across its business.
Seeking Alpha · 8h ago
Jim Cramer Says This Energy Stock Is 'Terrific,' Calls Casey's General Stores A 'Winner'
Jim Cramer recommended selling Petróleo Brasileiro S.A. – Petrobras (PBR) on CNBC's "Mad Money Lightning Round" The CNBC host recommended buying Cheniere Energy, Inc. And Broadcom Inc. Cramer also recommended buying Recursion Pharmaceuticals and Casey's General Stores.
Benzinga · 9h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 9h ago
Recursion Pharmaceuticals (NASDAQ:RXRX) AI-Driven Drug Discovery Offers Promising Upside
TipRanks · 17h ago
Weekly Report: what happened at RXRX last week (0415-0419)?
Weekly Report · 2d ago
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha · 5d ago
Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Pharmaceuticals is a biotech that's planning to go big on artificial intelligence for drug development. The company has no products approved for sale but could have as many as five medicines on the market by early 2029. Recursion has around 20 petabytes of data from real patients to use in its AI-enabled drug-discovery platform. But the company is still in its infancy.
The Motley Fool · 04/17 11:00
Recursion Pharmaceuticals Welcomes New Director and C-Suite Executive
TipRanks · 04/16 12:12
Press Release: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer. Dr. Khan, formerly the Chief Data Science Officer at Johnson & Johnson, will also join Recursion's Board of Directors. She will lead the company's research and development, and build its emerging commercial capabilities. Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery.
Dow Jones · 04/16 12:00
Weekly Report: what happened at RXRX last week (0408-0412)?
Weekly Report · 04/15 09:20
Cathie Wood's Ark Invest Sells $20M+ Coinbase Shares As Bitcoin Trades Over $70K, Buys Palantir, Sells Nvidia Stock
Cathie Wood’s Ark Invest made significant trades involving Coinbase Global, Inc., Palantir Technologies Inc. And Nvidia Corp. On Thursday. Ark Invest sold 77,561 shares of Bitcoin and purchased shares of the company. The firm also sold shares of PalantIR and bought shares of Nvidia on the same day.
Benzinga · 04/12 02:54
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
Recursion Pharmaceuticals stock may double or more within the next five years. The company's shares have plunged more than 70% since its IPO in 2021. Recursion focuses on machine learning and artificial intelligence for drug discovery and development. The firm has five candidates in phase 2 clinical studies and has no product sales.
The Motley Fool · 04/10 09:50
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Seeking Alpha · 04/10 09:12
6 Under-the-Radar AI Stocks That Analysts Expect to Rally
Morgan Stanley lists 6 under-the-radar AI stocks it considers high conviction picks. The company says the market for artificial intelligence is expected to reach a market size of $2.58 trillion by 2032. These are six companies Morgan Stanley believes are worth adding to your portfolio due to the potential of AI.
Barchart · 04/10 08:24
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
Recursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotechnology company. The company has an average price target of $16.0 for the next 12 months. 5 analysts have evaluated the company in the last three months. The 12-month price targets offer insights on the company's growth prospects. Recursion pharmaceuticals has a decline in revenue growth compared to peers.
Benzinga · 04/09 14:00
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
TipRanks · 04/09 10:30
Recursion Pharmaceuticals Price Target Maintained With a $17.00/Share by Needham
Dow Jones · 04/09 10:30
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Benzinga · 04/09 10:20
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
Artificial intelligence is becoming a competitive differentiator for biopharma companies. Ginkgo Bioworks is using AI to help other companies produce more cheaply and efficiently. Recursion Pharmaceuticals is at the forefront of the AI revolution in healthcare. The company isn't profitable yet, but it's swinging for the fences.
The Motley Fool · 04/08 13:00
Weekly Report: what happened at RXRX last week (0401-0405)?
Weekly Report · 04/08 09:22
More
Webull provides a variety of real-time RXRX stock news. You can receive the latest news about Recursion Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.